MTOR and Alzheimer disease: In response to elevated levels of mTOR, administration of rapamycin was shown to decrease the pathological hallmarks of AD and associated cognitive deficits in 3xTg-AD, Tg2576 and hAPP (J20) mouse models (Caccamo et al., 2014, Caccamo et al., 2010, Harrison et al., 2009, Lin et al., 2013, Spilman et al., 2010, Wilkinson et al., 2012).